The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat ... a tablet dosage form of treprostinil, to delay disease ...

Can buprenorphine sublingual tablets be used for pain? If so, what is the dosage? No, the sublingual tablet form of buprenorphine is not approved to treat pain. It is only approved to treat opioid ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

The dosage for Ofev is typically 150 milligrams twice per day, regardless of the condition being treated. Ofev is taken to treat certain types of lung disease. Ofev comes as a capsule you swallow ...

The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for ...

With this approval, YUFLYMA is now fully interchangeable with the reference product, Humira ® (adalimumab), across all marketed dosage forms and strengths. YUFLYMA is a high-concentration ...

However, it has been outperformed in head-to-head trials by Tremfya, as well as Skyrizi, which approached $12 billion in sales last year and is viewed as J&J's fiercest rival in the market.

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

The US Food and Drug Administration (FDA) has approved a new tablet formulation of Brukinsa (zanubrutinib), which is expected to replace the current capsule formulation in October 2025. Brukinsa, a ...